Information Provided By:
Fly News Breaks for March 4, 2020
VYGR
Mar 4, 2020 | 10:59 EDT
H.C. Wainwright analyst Debit Chattopadhyay lowered the firm's price target on Voyager Therapeutics to $18 from $26 after the company's FY19 update clarified the enrollment threshold into the Phase 2, RESTORE-1 program evaluating VY-AADC in Parkinson's disease. Though there is more clarity on enrollment into RESTORE-1, a concrete timeline for VY-HTT01 and the RESTORE programs remains key to investor sentiment going forward, said the analyst, who keeps a Buy rating on Voyager shares.
News For VYGR From the Last 2 Days
There are no results for your query VYGR